Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism

被引:22
|
作者
Markowitz, Daniel [1 ,2 ]
Ha, Grace [2 ]
Ruggieri, Rosamaria [1 ,2 ]
Symons, Marc [1 ,2 ]
机构
[1] Hofstra Northwell Sch Med, Hempstead, NY USA
[2] Feinstein Inst Med Res, Karches Ctr Oncol Res, 350 Community Dr, Manhasset, NY 11030 USA
来源
ONCOTARGETS AND THERAPY | 2017年 / 10卷
关键词
microtubules; mebendazole; ionizing radiation; radiosensitization; interphase; DNA damage response; MITOTIC CATASTROPHE; PROSTATE-CANCER; DNA-DAMAGE; APOPTOSIS; MITOSIS; REPAIR; CHEMOTHERAPY; KINASE;
D O I
10.2147/OTT.S143096
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: The cytotoxic effects of microtubule-targeting agents (MTAs) are often attributed to targeted effects on mitotic cells. In clinical practice, MTAs are combined with DNA-damaging agents such as ionizing radiation (IR) with the rationale that mitotic cells are highly sensitive to DNA damage. In contrast, recent studies suggest that MTAs synergize with IR by interfering with the trafficking of DNA damage response (DDR) proteins during interphase. These studies, however, have yet to demonstrate the functional consequences of interfering with interphase microtubules in the presence of IR. To address this, we combined IR with an established MTA, mebendazole (MBZ), to treat glioma cells exclusively during interphase. Materials and methods: To test whether MTAs can sensitize interphase cells to IR, we treated GL261 and GBM14 glioma cells with MBZ during 3-9 hours post IR (when the mitotic index was 0%). Cell viability was measured using a WST-1 assay, and radiosensitization was quantified using the dose enhancement factor (DEF). The effect of MBZ on the DDR was studied via Western blot analysis of H2AX phosphorylation. To examine the effects of MTAs on intracellular transport of DDR proteins, Nbs1 and Chk2, cytoplasmic and nuclear fractionation studies were conducted following treatment of glioma cells with MBZ. Results: Treatment with MBZ sensitized interphase cells to the effects of IR, with a maximal DEF of 1.34 in GL261 cells and 1.69 in GBM14 cells. Treatment of interphase cells with MBZ led to more sustained.H2AX levels post IR, indicating a delay in the DDR. Exposure of glioma cells to MBZ resulted in a dose-dependent sequestration of Chk2 and Nbs1 in the cytoplasm. Conclusion: This study demonstrates that MBZ can sensitize cancer cells to IR independently of the induction of mitotic arrest. In addition, evidence is provided supporting the hypothesis that MTA-induced radiosensitization is mediated by inhibiting DDR protein accumulation into the nucleus.
引用
收藏
页码:5633 / 5642
页数:10
相关论文
共 50 条
  • [31] Development of Novel Bis(indolyl)-hydrazide Hydrazone Derivatives as Potent Microtubule-Targeting Cytotoxic Agents against A549 Lung Cancer Cells
    Das Mukherjee, Dipanwita
    Kumar, N. Maruthi
    Tantak, Mukund P.
    Das, Amlan
    Ganguli, Arnab
    Datta, Satabdi
    Kumar, Dalip
    Chakrabarti, Gopal
    BIOCHEMISTRY, 2016, 55 (21) : 3020 - 3035
  • [32] The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells.
    Mould, Emily
    Berry, Philip
    Jamieson, David
    Hill, Christopher
    Tan, Niu
    Elliott, Sarah
    Durkacz, Barbara
    Newell, David
    Willmore, Elaine
    CANCER RESEARCH, 2013, 73 (08)
  • [33] Hsp90 inhibitors sensitize colorectal cancer cells to ionizing radiation in vitro.
    Li, M.
    Kinzel, L.
    Friedl, A.
    Winssinger, N.
    Ganswindt, U.
    Belka, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 23 - 23
  • [34] Stiffening of DU145 prostate cancer cells driven by actin filaments - microtubule crosstalk conferring resistance to microtubule-targeting drugs
    Kubiak, Andrzej
    Chighizola, Matteo
    Schulte, Carsten
    Bryniarska, Natalia
    Wesolowska, Julita
    Pudelek, Maciej
    Lasota, Malgorzata
    Ryszawy, Damian
    Basta-Kaim, Agnieszka
    Laidler, Piotr
    Podesta, Alessandro
    Lekka, Malgorzata
    NANOSCALE, 2021, 13 (12) : 6212 - 6226
  • [35] Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds
    Tagliamento, Marco
    Genova, Carlo
    Rossi, Giovanni
    Coco, Simona
    Rijavec, Erika
    Dal Bello, Maria Giovanna
    Boccardo, Simona
    Grossi, Francesco
    Alama, Angela
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (06) : 513 - 523
  • [36] A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation
    Hatano, Koji
    Kumar, Binod
    Zhang, Yonggang
    Coulter, Jonathan B.
    Hedayati, Mohammad
    Mears, Brian
    Ni, Xiaohua
    Kudrolli, Tarana A.
    Chowdhury, Wasim H.
    Rodriguez, Ronald
    DeWeese, Theodore L.
    Lupold, Shawn E.
    NUCLEIC ACIDS RESEARCH, 2015, 43 (08) : 4075 - 4086
  • [37] G-quadruplex telomere targeting agents sensitize cancer cells to cis-platinum
    Neidle, Stephen
    Gunaratnam, Mekala
    Greciano, Olga
    Martins, Cristina
    Kelland, Lloyd
    CANCER RESEARCH, 2006, 66 (08)
  • [38] Synergistic Antitumor Activities of Sepantronium Bromide (YM155), a Survivin Suppressant, in Combination with Microtubule-Targeting Agents in Triple-Negative Breast Cancer Cells
    Kaneko, Naoki
    Yamanaka, Kentaro
    Kita, Aya
    Tabata, Kenji
    Akabane, Takafumi
    Mori, Masamichi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2013, 36 (12) : 1921 - 1927
  • [39] Dual Mechanism of Action of the Novel Microtubule-targeting Drug BAL27862 (active Moiety of the Prodrug BAL101553): Targeting Tumor and Vascular Cells
    Bachmann, F.
    Lane, H.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 128 - 128
  • [40] AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models
    Bush, Tammy L.
    Payton, Marc
    Heller, Scott
    Chung, Grace
    Hanestad, Kelly
    Rottman, James B.
    Loberg, Robert
    Friberg, Gregory
    Kendall, Richard L.
    Saffran, Douglas
    Radinsky, Robert
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11) : 2356 - 2366